Payment overview · 2025
General Payments
$2,101.39
72 reported records · 5 companies
Healthcare provider profile · identity verified
Maritza Yvette Baez, MD
Allopathic & Osteopathic Physicians|Family Medicine · BUFFALO, NY · NPI 1285849877
Verified facts
What the public records show
CMS Open Payments records show Maritza Yvette Baez, MD received $2,101.39 in general payments during 2025 across 72 reported records.
AstraZeneca Pharmaceuticals LP accounted for 47.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Farxiga by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,007.50 | 47.9% | 23 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $561.16 | 26.7% | 17 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $274.83 | 13.1% | 21 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $138.86 | 6.6% | 10 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $119.04 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,101.39 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $598.27 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $467.60 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $356.31 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $337.22 | 8 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $274.83 | 21 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $144.84 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $119.04 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $115.96 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $92.24 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $33.63 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.90 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 81 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
81 | 19 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
55 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 497 | 169 |
| Amlodipine Besylate | Amlodipine Besylate | 264 | 86 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 60 |
| Gabapentin | Gabapentin | 125 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 54 |
| Metformin Hcl | Metformin Hcl | 105 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 35 |
| Omeprazole | Omeprazole | 95 | 40 |
| Lisinopril | Lisinopril | 93 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 92 | 30 |
| Ozempic | Semaglutide | 91 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 85 | 29 |
| Farxiga | Dapagliflozin Propanediol | 81 | 19 |
| Famotidine | Famotidine | 80 | 24 |
| Losartan Potassium | Losartan Potassium | 74 | 26 |
| Metformin Hcl Er | Metformin Hcl | 68 | 21 |
| Enalapril Maleate | Enalapril Maleate | 63 | 21 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 62 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 61 | 22 |
| Baclofen | Baclofen | 58 | 15 |
| Eliquis | Apixaban | 55 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 17 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 54 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 30 |
| Furosemide | Furosemide | 51 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 48 | 23 |
| Alendronate Sodium | Alendronate Sodium | 47 | 18 |
| Montelukast Sodium | Montelukast Sodium | 46 | 15 |
| Trazodone Hcl | Trazodone Hcl | 44 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 12 |
| Carvedilol | Carvedilol | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 15 |
| Potassium Chloride | Potassium Chloride | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | 12 |
| Meloxicam | Meloxicam | 28 | 12 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | 12 |
| Topiramate | Topiramate | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Clotrimazole | Clotrimazole | 26 | 15 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Prednisone | Prednisone | 24 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 21 | 11 |
| Valsartan | Valsartan | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 13 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,101.39 · 72 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, FARXIGA, NEXLETOL, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error